Accutane Safety and Risk Management Act

Summary

Accutane Safety and Risk Management Act - Requires the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to withdraw approval within 30 days for the sale of drugs that contain isotretinoin as an active ingredient, including Accutane. Allows the Secretary to approve subsequent supplemental applications for such drugs subject to certain restrictions, including safety reporting. Requires that distribution of such drugs be limited, including by: (1) allowing distribution only directly from manufacturers to pharmacists; (2) requiring pharmacists to register, receive education on side effects, dispense only those prescriptions from physicians at certified treatment centers, and file a statement of compliance; (3) developing educational materials for patients, including monthly questionnaires for patients to monitor the development of adverse side effects; (4) requiring patients to register, receive counseling on the drug, sign a statement providing informed consent for treatment, and undergo appropriate tests; and (5) limiting prescriptions to a 30-day supply with no refills. Specifies conditions for a clinic to be certified as a treatment center for a drug containing isotretinoin, including requiring each practitioner to meet certain conditions, such as requirements for registration, an agreement to prescribe in accordance with this Act, and reporting of adverse events. Requires the Secretary to monitor the distribution of such drugs to determine whether the drug is being distributed in accordance with this Act. Requires manufacturers and distributors of isotretinoin to report any information on adverse events associated with the drug to the Secretary. Requires the Secretary to conduct and support studies to explore the effects of isotretinoin on the central nervous system and behavior, including depression, suicide, and violent behavior.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 16 June 2004

   Introduced

   Referred to the House Committee on Energy and Commerce.

   Source: IntroReferral

2. 16 June 2004

   Introduced

   Introduced in House

   Source: IntroReferral

3. 16 June 2004

   Introduced

   Introduced in House

   Source: IntroReferral

4. 7 July 2004

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

5. 29 September 2004

   Introduced

   Sponsor introductory remarks on measure. (CR H7821-7822)

   Source: IntroReferral

Votes

No vote records are attached yet.

Versions

• Introduced in House · 16 June 2004 · Download file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 16 June 2004

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 16 June 2004

  ViewDownloadOpen at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

• Introduced in House

  summary · EN · 16 June 2004

  Open at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

• Rep. Stupak, Bart [D-MI-1] · D · Sponsor
• Rep. Smith, Christopher H. [R-NJ-4] · R · Sponsor
• Rep. Weldon, Dave [R-FL-15] · R · Sponsor
• Rep. Kilpatrick, Carolyn C. [D-MI-13] · D · Sponsor
• Rep. Wamp, Zach [R-TN-3] · R · Sponsor
• Rep. DeGette, Diana [D-CO-1] · D · Sponsor
• Rep. Burton, Dan [R-IN-5] · R · Sponsor
• Rep. DeLauro, Rosa L. [D-CT-3] · D · Sponsor
• Rep. Doyle, Michael F. [D-PA-14] · D · Sponsor
• Rep. Baca, Joe [D-CA-43] · D · Sponsor
• Rep. Gordon, Bart [D-TN-6] · D · Sponsor
• Rep. Stearns, Cliff [R-FL-6] · R · Cosponsor
• Del. Christensen, Donna M. [D-VI-At Large] · D · Cosponsor
• Rep. McDermott, Jim [D-WA-7] · D · Cosponsor
• Rep. Miller, Candice S. [R-MI-10] · R · Cosponsor
• · hsif00 · Standing

Related records

No cross-record relationships stored yet.